Generic Name and Formulations:
Methylphenidate 10mg, 15mg, 20mg, 30mg; delivered over 9hrs; transdermal patches.
Indications for DAYTRANA:
Attention deficit hyperactivity disorder.
<6yrs: not established. 6–17yrs: Initially apply one 10mg patch to hip 2hrs before desired effect, remove 9hrs after application; may remove earlier if shorter duration of effect or late day side effects appear. May titrate dose at 1-week intervals. Reevaluate periodically. Rotate application sites.
Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family. During or within 14 days of MAOIs.
History of drug dependence or alcoholism; monitor for abnormal behavior. Discontinue if contact sensitization is suspected; may develop systemic sensitization with other MPH formulations (see full labeling). Avoid exposing patch to direct external heat sources. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. History of vitiligo. Monitor for signs of skin depigmentation; discontinue if chemical leukoderma develops. Monitor growth, BP, HR, CBCs, differential, platelet counts. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), tricyclics (eg, imipramine, clomipramine, desipramine), SSRIs. May decrease effectiveness of antihypertensive agents. Caution with pressor agents. Risk of serotonin syndrome with serotonergic drugs.
Application site reactions (eg, erythema), decreased appetite, insomnia, nausea, vomiting, weight loss, tics, affect lability, anorexia, dizziness, abdominal pain, headache, irritability; priapism, hypertension, tachycardia, visual disturbances.
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Opioids: Clinician Concern and Prescribing Practices
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- CDC: 8.8% of Individuals in the United States Uninsured in First Half of 2018
- Patient Experiences Shed Light on Diagnostic Errors
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Wikipedia in Medical Education: An Educator's Guide to Crowdsourcing